Table of Contents
Overview
New York, NY – June 16, 2025 – Global Hepatitis C Market size is expected to be worth around US$ 243.8 Billion by 2034 from US$ 71.2 Billion in 2024, growing at a CAGR of 13.1% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 42.2% share with a revenue of US$ 30.0 Billion.
Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), continues to pose a significant global health challenge, affecting an estimated 58 million people worldwide, according to the World Health Organization (WHO). Despite the availability of highly effective antiviral treatments that can cure over 95% of infections, access to testing and therapy remains limited in many regions.
The disease is primarily transmitted through contact with infected blood, often via unsafe injection practices, inadequate sterilization of medical equipment, and, in some cases, transfusion of unscreened blood. Chronic hepatitis C can lead to severe liver damage, including cirrhosis and liver cancer, if left untreated.
Recent public health efforts have emphasized the importance of early diagnosis, especially through expanded screening among high-risk populations. WHO’s 2030 elimination targets include reducing new HCV infections by 80% and HCV-related deaths by 65%. To support these goals, several countries have launched national hepatitis action plans to improve awareness, increase treatment coverage, and expand harm reduction programs.
Breakthroughs in direct-acting antivirals (DAAs) have revolutionized treatment, offering short-course, oral regimens with minimal side effects. However, affordability and access remain major barriers in low- and middle-income countries. Global health stakeholders continue to call for collaborative efforts to scale up prevention, testing, and treatment to eliminate hepatitis C as a public health threat.
Key Takeaways
- Market Size and Growth: The global hepatitis C market generated a revenue of US$ 71.2 billion in 2024 and is projected to reach US$ 243.8 billion by 2033, registering a compound annual growth rate (CAGR) of 13.1% during the forecast period.
- Treatment Segment Analysis: The treatment landscape is categorized into vaccines, antiviral drugs, immune modulator drugs, and others. Among these, vaccines dominated the segment in 2023, accounting for a market share of 48.3%.
- Diagnosis Segment Overview: Diagnosis methods include liver biopsy, imaging tests, blood tests, and others. Within this segment, imaging tests held a significant share of 41.7%, reflecting strong clinical reliance for disease monitoring.
- Route of Administration Insights: Based on the route of administration, the market is segmented into oral, parenteral, and others. The oral route emerged as the leading segment, contributing 58.3% of the total market revenue.
- End-User Analysis: Key end-users include hospitals, homecare, specialty clinics, and others. The hospital segment remained dominant, securing a 52.2% share of the hepatitis C market.
- Regional Performance: North America led the global hepatitis C market in 2023, holding a market share of 42.2%, driven by high treatment adoption and advanced healthcare infrastructure.
Segmentation Analysis
- Treatment Segment Analysis: In 2023, the vaccines segment dominated the treatment category, holding 48.3% of the market share. This growth is attributed to increased focus on preventive care and the rising need to control hepatitis C among high-risk populations. Ongoing R&D efforts and expanding global vaccination initiatives are expected to strengthen this segment. As governments prioritize immunization strategies, vaccine-based solutions are projected to see higher adoption, playing a central role in reducing hepatitis C transmission rates.
- Diagnosis Segment Analysis: Imaging tests accounted for a significant 41.7% market share in 2023, driven by the increasing use of non-invasive diagnostic methods. Tools such as ultrasound and elastography offer a safe and effective way to evaluate liver damage and fibrosis, reducing reliance on invasive liver biopsies. As clinical emphasis grows on early detection and disease monitoring, the imaging segment is expected to expand further, fueled by technological advancements and increasing awareness of non-invasive diagnostic approaches.
- Route of Administration Analysis: The oral route emerged as the leading mode of administration, capturing 58.3% of the revenue in 2023. This dominance is attributed to the widespread acceptance of oral direct-acting antivirals (DAAs), which provide high cure rates, fewer side effects, and greater convenience. The preference for non-invasive treatment continues to rise among patients and physicians. With new oral therapies improving treatment outcomes, the oral administration segment is likely to maintain its strong position in the hepatitis C market.
- End-User Segment Analysis: Hospitals led the end-user segment with a 52.2% market share in 2023, reflecting their critical role in hepatitis C diagnosis and treatment. These facilities offer comprehensive care, including access to advanced diagnostics and specialized treatment protocols. As the incidence of hepatitis C rises globally, hospitals are expected to see increased patient volumes. Enhanced hospital-based programs, including integration with telehealth services, are projected to further support this segment’s continued growth throughout the forecast period.
Market Segments
By Treatment
- Vaccines
- Antiviral Drugs
- Immune Modulator Drugs
- Others
By Diagnosis
- Liver Biopsy
- Imaging Tests
- Blood Tests
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Regional Analysis
In 2023, North America led the global hepatitis C market with a revenue share of 42.2%, driven by advanced treatment availability, robust screening programs, and targeted government initiatives. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 66,700 new chronic hepatitis C cases were reported in 2022, emphasizing the persistent need for effective interventions. The introduction of direct-acting antivirals (DAAs), with cure rates above 95%, has significantly improved treatment outcomes.
The U.S. Department of Health and Human Services (HHS) confirmed that over 1 million individuals have received DAA-based treatment, facilitated by Medicaid expansions and state-level programs. In Canada, hepatitis C-related healthcare spending rose by 15% between 2022 and 2023, according to the Canadian Institute for Health Information (CIHI), underlining regional commitment to disease elimination.
The Asia Pacific region is projected to record the fastest CAGR during the forecast period due to increasing prevalence, enhanced healthcare access, and aggressive elimination strategies. WHO estimated over 70 million people in Asia Pacific were living with chronic hepatitis C in 2022. Government-backed initiatives in India, China, and Australia have led to notable increases in screening, treatment uptake, and availability of affordable generics. These developments are expected to strengthen Asia Pacific’s role in the global hepatitis C landscape.
Emerging Trends
- Increase in Acute Infections: During 2023, 47 states and the District of Columbia reported 4,966 acute hepatitis C cases, corresponding to an estimated 69,000 new infections nationwide. This represents a concerning rise in acute infections, particularly among adults aged 18–39, suggesting that recent prevention efforts have not fully curbed transmission in higher-risk groups.
- Expansion of Universal Screening: Universal hepatitis C screening has been recommended for all adults aged 18 and older at least once in a lifetime and for all pregnant women during each pregnancy, except where prevalence is under 0.1%. This shift toward routine testing in primary care and obstetric settings aims to identify undiagnosed cases earlier and link individuals to care.
- Advancements in Diagnostic Technology: Innovative diagnostic assays, such as HCV core antigen tests, are in advanced stages of development. These one-step tests enable simultaneous detection of active infection without requiring multiple laboratory visits, which can streamline diagnosis and accelerate treatment initiation in both high- and low-resource settings.
- Ambitious Elimination Targets: Global and national plans now aim to scale up hepatitis C testing to 90% of those infected and treatment to at least 80% of diagnosed cases by 2030. Modeling indicates that achieving these targets could prevent an estimated 2.1 million deaths and avert 10 million new infections worldwide, reflecting a growing commitment to disease elimination.
Use Cases
- Harm Reduction Programs for Injection Drug Users: In places with high rates of hepatitis C transmission among people who inject drugs, needle-exchange and safe-injection facilities have been implemented. Between 2020 and 2023, the reported rate of new infections in this group declined from 2.6 to 1.7 per 100,000 persons, demonstrating the impact of combined harm-reduction and testing initiatives.
- Routine Screening in Healthcare Settings: Primary care clinics and obstetric services have integrated hepatitis C testing into standard panels for adults and pregnant women. This approach has led to a marked increase in case identification: in 2023, over 100,000 new chronic cases were reported, many detected through routine screening rather than risk-based testing.
- Direct-Acting Antiviral Treatment: Once diagnosed, patients have access to direct-acting antivirals (DAAs) that achieve cure rates exceeding 95% after 8–12 weeks of therapy. More than 1 million individuals in the United States have been treated with DAAs since their approval, resulting in substantial reductions in liver-related complications.
- National Elimination Campaigns: Countries are launching coordinated elimination programs that combine mass screening, rapid diagnostics, and subsidized DAA treatment. Modeling suggests that scaling up testing to 90% and treating 80% of diagnosed cases could avert 2.1 million hepatitis C–related deaths by 2030, underscoring the value of integrated public health strategies.
Conclusion
Hepatitis C remains a critical public health issue despite the availability of highly effective treatments. With an estimated 58 million people affected globally, efforts to eliminate the disease by 2030 focus on expanding access to testing, treatment, and preventive care. Innovations in diagnostics and oral antiviral therapies have improved outcomes, but barriers such as affordability and limited access in low-income regions persist.
The market continues to grow, driven by rising awareness, universal screening programs, and national elimination campaigns. Sustained global collaboration is essential to achieving WHO’s elimination targets and reducing the disease burden worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
